ORTX - Orchard Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
2,607
2,076
-
0
Cost of Revenue
756
422
-
0
Gross Profit
1,851
1,654
-
0
Operating Expenses
Research Development
103,890
205,319
32,527
16,206
Selling General and Administrative
50,639
31,366
5,985
2,997
Total Operating Expenses
154,529
236,685
38,512
19,203
Operating Income or Loss
-152,678
-235,031
-38,512
-19,203
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
7,638
5,506
-1,179
138
Income Before Tax
-145,040
-229,525
-39,691
-19,065
Income Tax Expense
-1,971
970
53
20
Income from Continuing Operations
-143,069
-230,495
-39,744
-19,085
Net Income
-143,069
-230,495
-39,744
-19,085
Net Income available to common shareholders
-143,069
-230,495
-39,744
-19,085
Reported EPS
Basic
-
-10.22
-4.48
-1.89
Diluted
-
-10.22
-4.48
-1.89
Weighted average shares outstanding
Basic
-
22,559
8,873
10,096
Diluted
-
22,559
8,873
10,096
EBITDA
-
-233,832
-38,210
-19,197